Provided by the Academy for Continued Healthcare Learning (ACHL).
This activity is supported by an educational grant from AstraZeneca.
This activity features symposium highlights from the C3 Advanced Endovascular and Coronary Intervention Global Summit, which took place June 2018 in Orlando, Florida. A panel of faculty experts discuss topics in ACS treatment optimization, including: Improving individualized dual antiplatelet regimens in complex patients; Performing genetic testing to guide DAPT; Weighing index lesion complexity versus patient characteristics to optimize DAPT benefits.
This activity is intended for interventional cardiologists, cardiologists, vascular surgeons, cardiothoracic surgeons, technologists, nurses, and other clinicians who manage thrombotic risks across diverse patient populations.
Upon completion of this activity, participants will be able to:
Discuss the latest guidelines for antiplatelet therapy in ACS
Compare and contrast the pharmacodynamic properties of antiplatelet therapies
Outline the most recent efficacy and safety data of antiplatelet therapies and dual antiplatelet regimens for patients undergoing PCI
Discuss the advantages and challenges of maintaining longer term antiplatelet therapy for reduction of cardiovascular risk
Conflict Of Interest Disclosure Policy
ACHL requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. The following financial relationships have been provided:
Marc P. Bonaca, MD, MPH Assistant Professor, Harvard Medical School Associate Physician, Brigham and Women’s Hospital Boston, MA
Dr. Bonaca discloses the following: Consultant: Aralez, AstraZeneca, Bayer, Janssen, Merck Research Support: MedImmune, Merck, Amgen, AstraZeneca
Bryan Kluck, DO Cardiologist Lehigh Valley Health Network Allentown, PA
Dr. Kluck discloses the following: Board Member/Advisory Panel: Boston Scientific Corporation, Janssen Speakers Bureau: Aralez, Boehringer Ingelheim
Sandeep Nathan, MD, MSc Associate Professor of Medicine Medical Director, Cardiac Intensive Care Unit Director, Interventional Cardiology Fellowship Program Co-Director, Cardiac Catheterization Laboratory Heart and Vascular Center, University of Chicago Medicine Chicago, IL
Dr. Nathan discloses the following: Consultant: AstraZeneca, Cardiovascular Systems, Inc., Janssen, Maquet, Medtronic, Merit Medical, Terumo Medical Corporation Speakers Bureau: Cardiovascular Systems, Inc., Janssen
Christian T. Ruff, MD, MPH Assistant Professor of Medicine, Harvard Medical School Associate Physician, Brigham and Women's Hospital Boston, MA
Dr. Ruff discloses the following: Board Member/Advisory Panel: Bayer Healthcare, Boehringer Ingelheim, Daiichi Sankyo, Inc., Janssen, Portola Consultant: Boehringer Ingelheim, Daiichi Sankyo, Inc. Research Support: Boehringer Ingelheim, Daiichi Sankyo, Inc., MedImmune, NIH
Accredited Provider Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of ACHL and Interventional Academy. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This activity will take approximately 45 minutes to complete. To receive credit, participants are required to complete the pre-test, view the activity, and complete the post-test and evaluation. To receive credit, 66% must be achieved on the post-test. A certificate will be immediately available. There is no fee for the generation of the certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
If you have any questions relating to the accreditation of this activity, please call ACHL at (877) 444-8435, ext. 125.